ClinicalTrials.gg
CompletedNCT02419612Updated Jun 23, 2020Results posted

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

A Phase 3 interventional study of Saxagliptin and Dapagliflozin in Diabetes, sponsored by AstraZeneca. Completed at 84 sites in 10 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2020-06-23.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
444
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies testing saxagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. saxagliptin · Diabetes Mellitus.

Enrollment
3rd of 10
444 · median 66
Started
2015
with 1 other
Phase 3
4 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
7 of 10
AstraZeneca

Among the 10 studies testing saxagliptin in Diabetes Mellitus, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 3, and was the 9th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,073 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 10 studies testing saxagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 89 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing saxagliptin in Diabetes Mellitus as a file.
02

Study summary

This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the addition of glimepiride to metformin in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on Metformin Alone. We will compare the change from baseline in HbA1c achieved with saxagliptin, in co-administration with dapagliflozin, added to current background therapy with metformin compared to glimepiride added to current background therapy with metformin ≥1500 mg at Week 52.

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Subjects must be willing and able to give signed and dated written
  • Patients with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control
  • Subjects should have been taking the same daily dose of metformin ≥ 1500 mg
  • Fasting Plasma Glucose ≤ 270 mg/dL (≤15 mmol/L)
  • Males and females, aged ≥18 years old at time of screening visit
  • Women of (WOCBP) must have a negative serum or urine pregnancy test
  • WOCBP and males must agree to follow instructions for method(s) of for the duration of treatment with study drug

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of type I diabetes
  • History of diabetic ketoacidosis
  • Cardiovascular/vascular diseases within 3 months of the enrollment
  • Renal disease
  • Hepatic diseases
  • History of, or currently, acute or chronic pancreatitis
  • Hematological and oncological disease/conditions
  • Patients who have to therapy being studied
  • Patients on weight loss program(s)
  • Replacement or chronic systemic therapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
444 participants (actual)

Study arms

  • Experimental
    Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo

    Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally

    Drug: Saxagliptin · Drug: Dapagliflozin · Other: Placebo

  • Experimental
    Glimepiride or Placebo

    Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally

    Drug: Glimepiride · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52

    To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Change From Baseline in Total Body Weight at Week 52

    To examine whether the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.

    Time frame: Baseline and Week 52

  2. Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52

    Therapeutic glycemic response was defined as HbA1c \<7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 52 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c.

    Time frame: At Week 52

  3. Change From Baseline in Systolic Blood Pressure (SBP) at Week 52

    To examine whether the change from baseline in SBP with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.

    Time frame: Baseline and Week 52

  4. Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period

    Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after the 52-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 52 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 52-week short -term treatment period.

    Time frame: Up to Week 52

  5. Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.

    Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 156-week treatment period.

    Time frame: Up to Week 156

  6. Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156

    Therapeutic glycemic response was defined as HbA1c \<7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 156 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c.

    Time frame: At Week 156

  7. Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.

    Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. Time to treatment intensification curves were generated using Kaplan-Meier estimates and compared using a Cox proportional hazards model.

    Time frame: Up to Week 156

07

Results

Posted Oct 19, 2018

Participant flow

A total of 444 subjects were randomized in this international, multi-center study which was conducted at 88 centers in 10 countries between 14 Aug 2015 and 18 September 2019.

Short-term Treatment Period
Participant flow — Short-term Treatment Period
MilestoneDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Started227217
Recevied treatment227216
Completed210194
Not completed1723
Withdrew: Adverse event11
Withdrew: Death02
Withdrew: Lost to follow-up66
Withdrew: Withdrawal by subject99
Withdrew: Subject request to discontinue treatment11
Withdrew: Non-compliance with study drug02
Withdrew: Worsening of liver function01
Withdrew: Subject moved out of state01
Long-term Treatment Period
Participant flow — Long-term Treatment Period
MilestoneDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Started196186
Received treatment196183
Completed174164
Not completed2222
Withdrew: Non-compliance with study drug11
Withdrew: Lost to follow-up64
Withdrew: Lack of efficacy11
Withdrew: Death01
Withdrew: Adverse event05
Withdrew: Other44
Withdrew: Subject decision24
Withdrew: Withdrawal by subject82

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) at Week 52

To examine whether the mean change from baseline in HbA1c with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · % HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52
% HbA1cDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52-1.35 (-1.49 to -1.22)-0.98 (-1.12 to -0.84)
Statistical analysis
  • Dapagliflozin 10mg and Saxagliptin 5mg vs Titrated Glimepiride · Mixed Models Analysis · p = <0.001 · Least squares (ls) mean difference: -0.37 · 95% CI -0.57 to -0.18Adjusted for for treatment, baseline HbA1c, visit, treatment-by-visit interaction, and baseline HbA1c-by-visit interaction.
SecondaryChange From Baseline in Total Body Weight at Week 52

To examine whether the mean change from baseline in total body weight with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Total Body Weight at Week 52
kilogram (kg)Dapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Change From Baseline in Total Body Weight at Week 52-3.11 (-3.65 to -2.57)0.95 (0.38 to 1.51)
Statistical analysis
  • Dapagliflozin 10mg and Saxagliptin 5mg vs Titrated Glimepiride · Mixed Models Analysis · p = <0.001 · Ls mean difference: -4.06 · 95% CI -4.84 to -3.28Adjusted for for treatment, baseline body weight, visit, treatment-by-visit interaction, and baseline body weight-by-visit interaction.
SecondaryPercentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52

Therapeutic glycemic response was defined as HbA1c \<7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 52 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c.

Time frame:
At Week 52
Reported as:
Number · Percentage of subjects
Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52
Percentage of subjectsDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 5244.3 (37.45 to 51.32)34.3 (27.87 to 41.33)
Statistical analysis
  • Dapagliflozin 10mg and Saxagliptin 5mg vs Titrated Glimepiride · Regression, Logistic · p = 0.044 · Odds ratio (or): 1.5 · 95% CI 1.01 to 2.29Adjusted for baseline HbA1c value
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) at Week 52

To examine whether the change from baseline in SBP with co-administered saxagliptin 5 mg and dapagliflozin 10 mg plus metformin is superior to titrated glimepiride plus metformin after 52 weeks of double-blind treatment.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mmHg
Change From Baseline in Systolic Blood Pressure (SBP) at Week 52
mmHgDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Change From Baseline in Systolic Blood Pressure (SBP) at Week 52-2.6 (-4.4 to -0.8)1.0 (-0.9 to 2.9)
Statistical analysis
  • Dapagliflozin 10mg and Saxagliptin 5mg vs Titrated Glimepiride · Mixed Models Analysis · p = 0.007 · Ls mean difference: -3.6 · 95% CI -6.3 to -1.0Adjusted for treatment, baseline SBP, visit, treatment-by-visit interaction, and baseline SBP-by-visit interaction
SecondaryPercentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after the 52-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 52 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 52-week short -term treatment period.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of Subjects
Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period
Percentage of SubjectsDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period1.38.8
Statistical analysis
  • Dapagliflozin 10mg and Saxagliptin 5mg vs Titrated Glimepiride · Regression, Cox Proportional Hazards · p = 0.002 (This endpoint did not meet the required number of events (n=10) in each treatment arm, hence was excluded from sequential testing.) · Hazard ratio (hr): 0.15 · 95% CI 0.04 to 0.50
SecondaryPercentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. The values presented are the percentage of subjects requiring the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control during the 156-week treatment period.

Time frame:
Up to Week 156
Reported as:
Number · Percentage of Subjects
Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.
Percentage of SubjectsDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.37.055.6
Statistical analysis
  • Dapagliflozin 10mg and Saxagliptin 5mg vs Titrated Glimepiride · Regression, Cox Proportional Hazards · p = <0.001 · Hazard ratio (hr): 0.52 · 95% CI 0.39 to 0.68
SecondaryPercentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156

Therapeutic glycemic response was defined as HbA1c \<7.0%. Subjects rescued or discontinued prior to, and subjects with missing measurements at Week 156 were treated as non-responders. The percentage of subjects with a therapeutic glycemic response is based on the logistic regression method with adjustment for baseline HbA1c.

Time frame:
At Week 156
Reported as:
Number · Percentage of Subjects
Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156
Percentage of SubjectsDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 15621.4 (16.30 to 27.64)11.7 (8.03 to 16.82)
Statistical analysis
  • Dapagliflozin 10mg and Saxagliptin 5mg vs Titrated Glimepiride · Regression, Logistic · p = 0.006 · Odds ratio (or): 2.1 · 95% CI 1.23 to 3.42Adjusted for baseline HbA1c value.
SecondaryTime to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.

Treatment intensification was defined as the addition of insulin or other glucose-lowering agent for rescue therapy or discontinuation for lack of glycemic control. Time to treatment intensification was censored after 156-week treatment period if treatment intensification had not occurred by then. Subjects rescued at Week 156 were counted as having an event for the analysis. Time to treatment intensification curves were generated using Kaplan-Meier estimates and compared using a Cox proportional hazards model.

Time frame:
Up to Week 156
Reported as:
Median · Weeks
Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.
WeeksDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.NA (NA to NA)92.3 (73.0 to 105.7)
Statistical analysis
  • Dapagliflozin 10mg and Saxagliptin 5mg vs Titrated Glimepiride · Regression, Cox Proportional Hazards · p = <0.001 · Hazard ratio (hr): 0.52 · 95% CI 0.39 to 0.68

Adverse events

Collected over All adverse events (AEs), including serious adverse events (SAEs), were collected on or after the date of first dose of short-term study medication and up to and including 4 days (other AEs) or 30 days (SAEs) after last dose. Up to a total of 160 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin 10mg and Saxagliptin 5mg1/227 (0.4%)29/227 (12.8%)99/227 (43.6%)
Titrated Glimepiride3/216 (1.4%)24/216 (11.1%)106/216 (49.1%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
PneumoniaInfections and infestations1/2272/216
Ischaemic strokeNervous system disorders0/2272/216
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2272/216
Vertebrobasilar insufficiencyNervous system disorders2/2270/216
Abortion spontaneousPregnancy, puerperium and perinatal conditions2/2270/216
OsteoarthritisMusculoskeletal and connective tissue disorders2/2270/216
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders2/2270/216
Vertigo positionalEar and labyrinth disorders0/2271/216
Obstructive pancreatitisGastrointestinal disorders0/2271/216
Non-cardiac chest painGeneral disorders0/2271/216
Most frequent other events
Showing 10 of 11
Most frequent other events
EventDapagliflozin 10mg and Saxagliptin 5mgTitrated Glimepiride
Urinary tract infectionInfections and infestations31/22721/216
Upper respiratory tract infectionInfections and infestations23/22721/216
NasopharyngitisInfections and infestations14/22719/216
HypertensionVascular disorders7/22718/216
HeadacheNervous system disorders18/22716/216
BronchitisInfections and infestations11/22717/216
DyslipidaemiaMetabolism and nutrition disorders2/22713/216
InfluenzaInfections and infestations9/22712/216
PharyngitisInfections and infestations6/22712/216
DiarrhoeaGastrointestinal disorders10/22712/216

Baseline characteristics

Baseline characteristics are presented for the randomized subjects data set which included all randomized subjects who received at least 1 dose of study medication during the double-blind treatment period.

Age, Continuous
Age, Continuous(Years)Dapagliflozin 10mg and Saxagliptin 5mgTitrated GlimepirideTotal
Mean56.1 ± 10.1156.1 ± 9.2356.1 ± 9.68
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin 10mg and Saxagliptin 5mgTitrated GlimepirideTotal
Female110115225
Male117101218
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapagliflozin 10mg and Saxagliptin 5mgTitrated GlimepirideTotal
American Indian Or Alaska Native111021
Black Or African American459
Native Hawaiian Or Other Pacific Islander011
Other6410
White206196402
08

Study locations

84 sites
  • Research Site
    Birmingham, Alabama 35211, United States
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Tempe, Arizona 85283, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Sacramento, California 95823, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Jacksonville, Florida 32207, United States
  • Research Site
    Jacksonville, Florida 32277, United States
  • Research Site
    Kissimmee, Florida 34744, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33174, United States
  • Research Site
    New Port Richey, Florida 34652, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Edina, Minnesota 55435, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Greer, South Carolina 29651, United States
  • Research Site
    Bristol, Tennessee 37620, United States
  • Research Site
    Knoxville, Tennessee 37912, United States
  • Research Site
    Dallas, Texas 75230, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Cheb, 350 02, Czechia
  • Research Site
    Hradec Kralove, 503 41, Czechia
  • Research Site
    Krnov, 794 01, Czechia
  • Research Site
    Kromeriz, 767 01, Czechia
  • Research Site
    Nachod, 54701, Czechia
  • Research Site
    Praha 4, 140 00, Czechia
  • Research Site
    Praha 4, 149 00, Czechia
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Leipzig, 04249, Germany
  • Research Site
    Ajka, 8400, Hungary
  • Research Site
    Balatonfüred, 8230, Hungary
  • Research Site
    Budapest, 1033, Hungary
  • Research Site
    Budapest, 1089, Hungary
  • Research Site
    Budapest, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Eger, 3300, Hungary
  • Research Site
    Gyula, 5700, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Nyíregyháza, 4405, Hungary
  • Research Site
    Zalaegerszeg, 8900, Hungary
  • Research Site
    Aguascalientes, 20230, Mexico
  • Research Site
    Chihuahua, 31237, Mexico
  • Research Site
    Cuautla, 62746, Mexico
  • Research Site
    Guadalajara, 44600, Mexico
  • Research Site
    Guanajuato, 38000, Mexico
  • Research Site
    Monterrey, 64460, Mexico
  • Research Site
    Veracruz, 91910, Mexico
  • Research Site
    Białystok, 15-351, Poland
  • Research Site
    Katowice, 40-648, Poland
  • Research Site
    Kraków, 31-156, Poland
  • Research Site
    Kraków, 31-261, Poland
  • Research Site
    Opole, 45-367, Poland
  • Research Site
    Oswiecim, 32-600, Poland
  • Research Site
    Poznań, 61-655, Poland
  • Research Site
    Warszawa, 00-465, Poland
  • Research Site
    Warszawa, 02-507, Poland
  • Research Site
    Wroclaw, 50-349, Poland
  • Research Site
    Łódź, 90-242, Poland
  • Research Site
    Brasov, 500269, Romania
  • Research Site
    Bucuresti, 020045, Romania
  • Research Site
    Bucuresti, 020359, Romania
  • Research Site
    Buzau, 120203, Romania
  • Research Site
    Galati, 800291, Romania
  • Research Site
    Oradea, 410032, Romania
  • Research Site
    Oradea, 410169, Romania
  • Research Site
    Ploiesti, 100163, Romania
  • Research Site
    Ploiesti, 100342, Romania
  • Research Site
    Satu-Mare, 440055, Romania
  • Research Site
    Targu, 540142, Romania
  • Research Site
    Timisoara, 300736, Romania
  • Research Site
    Novosibirsk, 630087, Russian Federation
  • Research Site
    Saint Petersburg, 195257, Russian Federation
  • Research Site
    Smolensk, 214018, Russian Federation
  • Research Site
    St. Petersburg, 190013, Russian Federation
  • Research Site
    St. Petersburg, 194354, Russian Federation
  • Research Site
    St. Petersburg, 196084, Russian Federation
  • Research Site
    St.-Petersburg, 195176, Russian Federation
  • Research Site
    Göteborg, 413 45, Sweden
  • Research Site
    Helsingborg, 25220, Sweden
  • Research Site
    Rättvik, 79530, Sweden
  • Research Site
    Dundee, DD1 9SY, United Kingdom
09

References and documents

Publications

  • Frias JP, Gonzalez-Galvez G, Johnsson E, Maaske J, Testa MA, Simonson DC, Dronamraju N, Garcia-Sanchez R, Peters AL. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1083-1093. doi: 10.1111/dom.13997. Epub 2020 Mar 9. PubMed 32052516 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Aug 2017, 24 months.

Results were first posted in Oct 2018, 1 year 1 month after primary completion.

Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 24 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2015
First posted
Apr 17, 2015
StartActual
Aug 14, 2015
Primary completionActual
Aug 29, 2017
CompletionActual
Sep 18, 2019
Results first posted
Oct 19, 2018
Last update
Jun 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02419612
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 17, 2015
Start date
Aug 14, 2015
Primary completion
Aug 29, 2017
Completion
Sep 18, 2019
Results posted
Oct 19, 2018
Last update
Jun 23, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Dapagliflozin · Glimepiride

Start the discussion